November 22, 2021 -- Cytovia Therapeutics and Cellectis have expanded their partnership on transcription activatorlike effector nuclease (TALEN) gene-edited iNK (NK cells derived from induced pluripotent stem cells, or iPSC) to allow for a broader collaboration in China.
Cellectis will continue its development of a new TALEN, which Cytovia uses to edit iPSCs, according to the two firms. The collaboration now includes a new chimeric antigen receptor target, which will be developed in China by CytoLynx Therapeutics, Cytovia's joint venture.
Cellectis will receive $20 million in Cytovia stock in addition to $805 million in development, regulatory, and sales milestones plus royalties, the two firms said.
Copyright © 2021 scienceboard.net